Singapore markets closed

Moderna, Inc. (MRNA)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
105.77-0.41 (-0.38%)
As of 09:35AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close106.18
Open106.18
Bid105.31 x 1000
Ask106.17 x 400
Day's range105.39 - 106.29
52-week range62.55 - 142.79
Volume86,659
Avg. volume3,784,295
Market cap40.498B
Beta (5Y monthly)1.59
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Zacks

    Analysts Estimate Moderna (MRNA) to Report a Decline in Earnings: What to Look Out for

    Moderna (MRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Reuters

    UPDATE 3-GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology

    GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday, accusing them of infringing GSK patents related to messenger RNA (mRNA) technology in the companies' blockbuster COVID-19 vaccines. GSK said in the lawsuit that Pfizer and BioNTech's Comirnaty vaccines violate the company's patent rights in mRNA-vaccine innovations developed "more than a decade before" the outbreak of the COVID-19 pandemic.

  • Reuters

    Pfizer vs Moderna battle over COVID vaccine patents begins in UK

    Pfizer and BioNTech asked a London court to revoke rival Moderna's patents over technology key to the development of vaccines for COVID-19, as the latest leg of a global legal battle began on Tuesday. Pfizer and its German partner BioNTech sued Moderna at London's High Court in September 2022, seeking to revoke patents held by Moderna, which hit back days later alleging its patents had been infringed. Moderna says Pfizer and BioNTech copied mRNA advances it had pioneered and patented well before the COVID-19 pandemic began in late 2019.